Mounjaro is intended for adults with a body mass index greater than 30, or greater than 27 with an obesity-related medical condition (i.e. diabetes, high blood pressure, high cholesterol, sleep apnea). Candidates must be willing and comfortable to use a weekly, injectable medication, and—this is critically important—willing to use the medication on a long-term basis. Obesity is a chronic and relapsing condition, therefore medications like Mounjaro are not designed for short-term use.
Please Note: The Mounjaro Weight Loss Medication Program is currently offered in Florida, Georgia, Maryland, North Carolina, South Carolina, Tennessee, and Virginia.
*While Mounjaro (tirzepatide) is currently FDA approved for the treatment of type 2 diabetes in adults, it has not yet received FDA approval for the specific treatment of obesity.